favezelimab

Merck study results signal blood cancer potential for new type of immunotherapy
BioPharma Dive
Thu, 05/26/22 - 10:40 pm
Merck
Bristol Myers Squibb
cancer
cancer immunotherapy
favezelimab
Hodgkin's lymphoma